Market Cap 9.36B
Revenue (ttm) 180.13M
Net Income (ttm) -465.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -258.64%
Debt to Equity Ratio 0.17
Volume 261,700
Avg Vol 326,908
Day's Range N/A - N/A
Shares Out 22.20M
Stochastic %K 20%
Beta -1.02
Analysts Strong Sell
Price Target $501.38

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 267 824 2827
Address:
Four Tower Bridge, Suite 200 200 Barr Harbor Drive, West Conshohocken, United States
Doozio
Doozio Oct. 27 at 7:52 PM
$MDGL if no faatch 💣 then wen 🌙?
0 · Reply
Wallst45
Wallst45 Oct. 26 at 7:50 PM
$MDGL things getting close to a buyout for Madrigal after RNA buyout today
3 · Reply
sarkar20
sarkar20 Oct. 26 at 6:43 PM
$MDGL One more rumor from Betaville cane good today, Novartis buying Avidity which Betaville rumored in August. They rumoured MDGL buyout in last December (2024), stilll no news on MDGL though!!
1 · Reply
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 25 at 2:52 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $417.55 Contracts: $MDGL December 18, 2026 $420 Calls Scale in: $103.64- $126.67 Scale out: $161.21-$207.27 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Wallst45
Wallst45 Oct. 24 at 1:58 PM
$MDGL BMY or GILD
1 · Reply
Wallst45
Wallst45 Oct. 23 at 7:09 PM
$MDGL yes easy buyout it’s coming in my opinion
1 · Reply
timfris
timfris Oct. 23 at 3:32 PM
$MDGL Viking CC talked about interest in MASH. What better company to buy than this?
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 23 at 1:00 PM
$MDGL I didn't buy yesterday as this is still being pushed down before the call. I will enter today and tomorrow if needed.
0 · Reply
Wallst45
Wallst45 Oct. 22 at 6:30 PM
$MDGL buyout anytime now
0 · Reply
Latest News on MDGL
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra

May 6, 2025, 4:20 PM EDT - 6 months ago

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra


Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.


Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 6:33 PM EST - 8 months ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity


Top 3 Health Care Stocks That May Dip This Month

Nov 25, 2024, 8:29 AM EST - 1 year ago

Top 3 Health Care Stocks That May Dip This Month

BFLY CNMD


Doozio
Doozio Oct. 27 at 7:52 PM
$MDGL if no faatch 💣 then wen 🌙?
0 · Reply
Wallst45
Wallst45 Oct. 26 at 7:50 PM
$MDGL things getting close to a buyout for Madrigal after RNA buyout today
3 · Reply
sarkar20
sarkar20 Oct. 26 at 6:43 PM
$MDGL One more rumor from Betaville cane good today, Novartis buying Avidity which Betaville rumored in August. They rumoured MDGL buyout in last December (2024), stilll no news on MDGL though!!
1 · Reply
BioRich
BioRich Oct. 25 at 5:10 AM
$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 25 at 2:52 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $417.55 Contracts: $MDGL December 18, 2026 $420 Calls Scale in: $103.64- $126.67 Scale out: $161.21-$207.27 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Wallst45
Wallst45 Oct. 24 at 1:58 PM
$MDGL BMY or GILD
1 · Reply
Wallst45
Wallst45 Oct. 23 at 7:09 PM
$MDGL yes easy buyout it’s coming in my opinion
1 · Reply
timfris
timfris Oct. 23 at 3:32 PM
$MDGL Viking CC talked about interest in MASH. What better company to buy than this?
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 23 at 1:00 PM
$MDGL I didn't buy yesterday as this is still being pushed down before the call. I will enter today and tomorrow if needed.
0 · Reply
Wallst45
Wallst45 Oct. 22 at 6:30 PM
$MDGL buyout anytime now
0 · Reply
Wallst45
Wallst45 Oct. 22 at 4:13 PM
$MDGL BTFD
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 22 at 2:01 PM
$MDGL if this goes into the teens- it's a no brainer to pick up a few.
0 · Reply
Quantumup
Quantumup Oct. 21 at 8:31 PM
Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.
0 · Reply
All_just_a_game
All_just_a_game Oct. 21 at 5:32 PM
$MDGL 250M revenue this quarter makes it an official billion dollar blockbuster run rate… and just getting started….
0 · Reply
Wallst45
Wallst45 Oct. 21 at 3:50 PM
$MDGL why no ER announcement yet ?
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 21 at 12:51 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $438.90 Contracts: $MDGL December 18, 2026 $440 Calls Scale in: $102.26- $124.98 Scale out: $159.07-$204.52 Can Easily Capture: 60% ROI Blended DTE: 425 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
shopno
shopno Oct. 20 at 11:35 PM
$IOVA that's exactly right! Another factor comes in play is competition or drug superiority. For instance, $VRNA got a superior COPD drug, and got 600-700% growth at BO since FDA approval in Q2 2024. For $MDGL , price had been muted even with solid revenue growth as the firstever MASH drug due to upcoming competitions and the fact that it's not most effective drug. For $IOVA the decline from post FDA approval took some time, but take a look at $TNXP -- another very poorly managed stock -- infamous for FOREVER reverse splitting. I had been in TNXP only since last reverse-split, and sold positions as it went 1000% on HYPE. And then it LOST 70% value since FDA approval -- even BEFORE the drug is launched. Just because TNXP had another F-grade managements, many investors who got in after the FDA approval in August dumped due to fear of failure launch by a low caliber CEO.
2 · Reply
Wallst45
Wallst45 Oct. 20 at 6:33 PM
$MDGL should get bought out soon
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 18 at 3:54 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $442.13 Contracts: $MDGL December 18, 2026 $450 Calls Scale in: $95.76- $117.04 Scale out: $148.96-$191.52 Can Easily Capture: 60% ROI Blended DTE: 427 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 2:05 PM
Enter: $MDGL NOV 21 2025 $440 CALLS Buy in Price: $35.00 - $38.00 Take Profit: $76.65 Stop Bleeding: $30.80 ROI Potential: 119% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
AMP19
AMP19 Oct. 17 at 9:33 AM
$MDGL blockbuster value. Easy double by next year.
0 · Reply
svertical1
svertical1 Oct. 17 at 5:28 AM
$IBRX $MDGL What Rev build- looks like for Biotech with $9.7B valuation. IMMUNITYBIO Rev growth accelerate faster with one more indication (Lymphopenia, Lung, etc). Madrigal Pharm $9.7B
0 · Reply